X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

By Yahoo! Finance   |   4 weeks ago
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

The Forward trial enrolls promising patients with chronic neutropenia, aligning well with the commercial market demand. The patient profile targets 50,000 diagnosed CN patients in the US, aiming for a broad label to cover the entire CN population.

Read More

Did you find this insightful?